|
|
Title: Plastically deformable
implant
United States Patent: 6,984,394
Issued: January 10, 2006
Inventors: Menz; Dirk-Henning (Diedorf,
DE); Dresp; Joachim (Munich, DE)
Assignee: Bausch & Lomb Incorporated
(Rochester, NY)
Appl. No.: 832516
Filed: April 27, 2004
|
|
|
Pharm Bus Intell
& Healthcare Studies
|
Abstract
The invention relates to a plastically
deformable implant for inserting into bodily orifices of the human or
animal body. Implants of this type are used, for example, in
ophthalmology, in particular, as vitreous body or lens replacements and in
dentistry, for example, for filling extraction cavities in jaw-bones.
Known implants, however, are not suitable for long-term use. The invention
aims to provide a deformable plastic implant which also has a long-term
application. This is achieved by the fact that the implant consists of a
gel which is not sealed, containing fluorocarbon and which is directly
introduced into the natural, or artificially created bodily orifice.
DETAILED DESCRIPTION
OF THE EMBODIMENTS
Because of their versatile and variable
properties, the fluorine-containing gels described above are suitable for
use as a starting material in the construction of a generic implant. For
such an implant to be of long-term use, however, it must be ensured that
the implant does not irreversibly liquefy when exposed to aqueous media.
In addition, the implant must have a long-term stability to mechanical and
thermal stresses. The stability of the implant material on exposure to
heat must be ensured, in particular, because the material must be
sterilized (121° C.) prior to inserting it into the bodily orifices. One
finding on which the present invention is based relates to the fact that
the gel structure of certain fluorine-containing gels is reversible and
can be completely recovered even after it has been considerably damaged.
Compared to the prior printed publications on fluorine-containing gels,
this finding comes as a surprise.
According to the present invention, the term fluorine-containing gel is
defined as a gel-like preparation which comprises a minimum of one
fluorocarbon. In especially useful embodiments of the present invention,
the fluorine-containing gel comprises essentially three components, i.e.,
a fluorocarbon, a fluorine-containing surface-active agent, and water. It
is possible for different additives to be added to the
fluorocarbon-containing and aqueous components. Certain compositions of
surface-active agents, fluorocarbons, and water form gels which are able
to completely recover their gel structure after they have been liquefied,
for example, by exposure to mechanical pressure or heat. This property of
the gels according to the present invention makes it possible for them to
be used as a generic implant over a long period of time. If the implant
material of such an implant that has been inserted into a bodily orifice
were to liquefy, for example, as a result of short-term pressure, the gel
structure, due to the reversibility described, would be able to recover
when in a state of rest. Thus, the implant according to the present
invention has a self-regulating restorative mechanism. This
self-regulating restorative mechanism of a polyaphron gel is attributable
to the stability of the aphrons that form the gel. After liquefaction, a
gel can restore its structure only if its "building blocks," the aphrons,
were not completely destroyed. If a sufficient number of intact aphrons
remain after liquefaction, a recovery is possible, and what comes as a
surprise is the fact that the aphron structure is transferred to the
homogenized regions of the surrounding liquid and that the gel structure
is restored in the entire liquid. The stability of the aphrons depends on
the intensity of the interaction between water, surface-active agent, and
perfluorocarbon, which in turn is determined by the surface properties and
the ability of the individual phases to spread on each other's surface. In
addition, an important aspect is the intensity of the interactions of the
molecules within the films that envelop the aphrons (water/surface-active
agent; perfluorocarbon/surface-active agent). Thus, the self-regulating
restorative mechanism is activated only if the surface properties of the
surface-active agent/water and/or surface-active agent/perfluorocarbon
film, on the one hand, and of the internal aphron phase, on the other
hand, are properly coordinated, i.e., if the strength of the
surface-active agent stabilizes the aphron structure. This can be
implemented through the use of fluorine-containing surface-active agents
of the general formula
RF—Rpol,
where RF stands for the linear or branched perfluoroalkyl
groups with more than 5 carbon atoms and Rpol stands for a
polar hydrocarbon residue which comprises a minimum of one functional
group which is selected from CO—NH(R), CO—N(R)2, COO—, COOR, SO3;
SO2N(R)2, CH2—O—R, PO2H, PO3H.
The molecular weight is preferably >400 g/mol, the surface tension in
aqueous solution is <30 mN/m and preferably <20 mN/m. The interfacial
tension in aqueous solution with respect to the nonpolar component is <25
mN/m, preferably <10 mN/m, and the concentration is <3%, preferably <0.1%.
With nonfluorinated surface-active agents, this can be achieved by means
of a strong cohesive effect with an HLB value greater than 25 (HLB=hydrophilic
lipophilic balance according to Griffin in J. Soc. Cosmet. Chem. 1 (1949),
p. 311).
Thus, the implant according to the present invention is able to resist
both thermal stress, for example, during sterilization, and mechanical
stress, for example, pressure exerted on the bodily orifice. Furthermore,
the ability of the implant according to the present invention to reverse
the damage to its structure prevents the destruction of the implant
material that is caused by diffusion processes in the bodily orifices. In
the implants according to the present invention, the light transmittance
of the fluorine-containing gels which in other gels is generally
considerably impaired as a result of these diffusion processes remains in
a dynamic equilibrium.
The biocompatibility of the implants according to the present invention is
ensured since ultrapurified starting materials and very small quantities
of surface-active agents (preferably <0.1%) are used. Moreover, the
surface-active agents used are histocompatible, intimately bonded to the
gel, and homogeneously distributed throughout the entire volume.
The implant according to the present invention is used, for example, in
ophthalmology as a vitreous body replacement. For this purpose, in
particular fluorine-containing gels with a high specific weight and, at
the same time, a high affinity to water-soluble substances are suitable.
Thus, for the first time, a tamponading material or implant with a
specific weight higher than that of water and, at the same time, the
capacity to absorb water-soluble ions are made available. After vitrectomy
and conventional procedures of retinal surgery, the plastically deformable
implant is injected into the space of the vitreous body. As a result of
the absorption of water, the plastically deformable implant expands. The
increase in volume caused by the absorption of water enhances the
tamponade effect mediated by the highly dense fluorocarbons. At the same
time, pressure builds inside the implant, and this pressure counteracts a
further expansion in volume and absorption of water. The dynamic
equilibrium that is established as a result is ensured by the structural
reversibility of the implant material and thus makes it possible for the
implant to be used for long-term applications.
An additional advantage of the implant according to the present invention
when used as a vitreous body replacement is the reduction of mechanical
injuries in the region of the retina. Such injuries are known to arise
when pure fluorocarbons are used as vitreous body replacement materials
and have been attributed to the high density of the fluorocarbons. Only
recently it was discovered that the injury is not caused by the static
pressure. Instead, the injuries are attributable to the fact that the
impalement of heavy fluids on the retina—as it occurs, for example, when
the head is moved rapidly—causes an increase in the mechanical pressure.
When using fluorine-containing gels as vitreous body replacement
materials, this effect can be prevented through the use of certain gels.
These gels are gels with a high viscosity/density ratio of >100 mPa cm3/g,
preferably >1000 mPa cm3g. Gels according to the present
invention of this type make possible a tamponade in the lower eye segment
without the development of motion-induced pressure peaks during sudden
jerky head movements. This is made possible by the viscosity which—in
comparison to that of pure fluorocarbons—is increased, and this increased
viscosity counteracts the acceleration forces and prevents the damaging
impact of heavy fluids on the retina. In this context, it is a particular
advantage that compared to the material properties of pure fluorocarbons,
those of the fluorine-containing gels are variable within wide limits.
In contrast to all other ophthalmological preparations on the basis of
fluorinated compounds, the implants according to the present invention as
ophthalmological preparations for application in the vitreoretinal region
can be used not only in procedures that aim at the reattachment of the
retina and as a short-term tamponading material. Instead, in addition to
the tamponade effect, these implants can also perform other functions of
the natural vitreous body. Thus, these implants open up new possibilities,
such as treating pathological changes in the vitreoretinal region or
suppressing morbid processes which may lead to a permanent injury to the
retina, e.g., injury to the Müller cells. For this purpose, the
preparations can be designed to ensure that they combine different and
even opposite properties in such a way that these can be activated in one
single treatment step. The application potential of the gels is enhanced
and expanded by the fluorocarbons that are contained in the gels which, as
is well known, have special properties, such as anti-inflammatory and
anti-gas properties.
The other known properties of fluorine-containing compounds that are of
advantage when such compounds are applied as ophthalmological preparations
are maintained or even enhanced in the implants according to the present
invention, thus, for example, the possibility of a laser treatment, the
tamponade properties, and the solubility of active ingredients. The
implants according to the present invention can be removed from the bodily
orifices using conventional methods, for example, vitrectomy.
The fluorine-containing implants according to the present invention can
also be used as intraocular lenses. For this particular purpose, it is
recommended that highly transparent gels be used which have an especially
high viscosity/density ratio; this can be achieved in particular through
the use of oligomer RFFH compounds as the
discontinuous phase, such as has been described in the European Patent No.
EP-A 545 174. In addition, the refractive index of the gels used should be
adjusted to a range from 1.334 to 1.338, which can be implemented, for
example, by using the following compounds:
| |
| |
Surface-active agent |
|
|
| |
Name/structure/abbreviation/ |
|
Biocompatibility |
| Fluorocarbon |
characteristics |
Refractive index |
(Draize test) |
| |
| |
| Perfluorophenanthrene |
Perfluoroalkyl ethanol |
1.3357 |
n.d. |
| |
oxethylate (Fluowet OTN, |
| |
Clariant) |
| |
σO = 18 mNm, σG
= 19 mNm |
| Perfluorophenanthrene |
Fluorinated amine oxide |
1.3361 |
n.d. |
| |
(Fluowet OX, Clariant) |
| |
σO = 22 mNm, σG
= 12 mNm |
| Perfluorophenanthrene |
Perfluoroalkyl ethanol |
1.3355 |
neg. |
| |
oxethylate (Fluowet OTL, |
| |
Clariant) |
| |
σO = 19 mNm, σG
= 10 mNm |
| Perfluorophenanthrene |
Perfluorooctanoic acid |
1.3362 |
neg. |
| |
tetraethyl piperazinium salt |
| |
(HO224) |
| |
σO = 16 mNm |
| Perfluorophenanthrene |
Perfluorooctanoic acid |
1.3360 |
neg. |
| |
N-methyl-D-glucamide (T14) |
| |
σO < 20 mNm |
| Perfluorophenanthrene |
Perfluorooctanoic acid |
1.3358 |
neg. |
| |
diethanolamide (HO31) |
| |
σO < 20 mNm |
| Perfluorophenanthrene |
Tetramethyl ammonium salt of |
1.336 |
neg. |
| |
perfluorooctanoic acid (E 749) |
| |
σO < 20 mNm |
| Perfluorophenanthrene |
Perfluorooctanoic acid |
1.336 |
neg. |
| |
amidotrimethyl ammonium |
| |
iodide (B98) |
| |
σO < 20 mNm |
| Perfluorophenanthrene |
Tetraethyl animonium salt of |
1.3359 |
neg. |
| |
perfluorooctanesulfonic acid |
| |
(B248) |
| |
σO < 20 mNm |
| Perfluorophenanthrene |
Perfluorodecanoic acid |
1.3357 |
neg. |
| |
N-(2-hydroxyethyl)-D- |
| |
glucamide (T21) |
| |
σO < 20 mNm |
| Perfluorophenanthrene |
Perfluorooctanoic acid |
1.336 |
neg. |
| |
N-(2-hydroxyethyl)-D- |
| |
glucamide (T16) |
| |
σO < 20 mNm |
| C6P13C8H17 |
Tetramethyl ammonium salt of |
1.3463 |
n.d. |
| |
perfluorooctanoic acid (E749) |
| |
σO < 20 mNm |
| (C6F13C2H4)3 |
Tetramethyl ammomium salt of |
1.3357 |
n.d. |
| |
perfluorooctanoic acid (E 749) |
| |
σO < 20 mNm |
| |
| neg. = negative |
| n.d. = not determined |
| σO = surface tension |
| σG = interfacial
tension with respect to the nonpolar component |
The implants according to the present
invention can be used instead of the artificial intraocular lenses made of
silicone, PMMA, or acrylic that are normally used for cataract operations.
After opening the capsular sac and removing the cloudy natural lens using
conventionally known methods, the implant material is injected, ensuring
that the entire capsular sac is completely filled with it. The implant
takes over the complete function of the natural lens, i.e., in spite of
the cataract operation, the accommodative capacity of the lens is
maintained. Due to the forces that are continuously acting on the implant,
the mechanical long-term stability is of very special importance in this
particular application.
The implants according to the present invention can also be used to
temporarily seal off bodily orifices and to temporarily separate tissue
parts, for example, in applications in which the implants are used as
expanders, or to stimulate the growth of bone. In dentistry, the implant
according to the present invention can be used in particular to
temporarily fill extraction cavities in the jaw bone and to expand tissue.
In addition, it can be used in orthopedic medicine as a biocompatible
lubricating film for joints and joint prostheses. After inserting the
implant material into the extraction cavities, these cavities are
encapsulated by sewing together the surrounding tissue. This prevents
leakage of the gel-like implant.
Claim 1 of 16 Claims
1. A plastically deformable
implant for insertion into bodily orifices of a human or animal body, the
implant formed by a gel which is not sealed and is directly introduced into
a natural or artificially created bodily opening, with the gel having a
polyaphron structure and comprising a fluorocarbon selected from the group
consisting of perfluorophenanthrene, C6F13C8H17
and (C6F13C2H4)3,
further comprising water, and a minimum of one fluorinated surface-active
agent of the general formula RF-Fpol, wherein:
RF stands for linear or branched perfluoroalkyl groups with more
than 5 carbon atoms;
Rpol stands for a polar hydrocarbon residue with a minimum of one
functional group which is selected from the group consisting of CO—NH(R),
CO—N(R)2, COO—, COOR, SO3—, SO2N(R)2,
CH2—O—R, PO2H, and PO3H (R=alkyl); and
the surface-active agent has a molecular weight of >400 g/mol, a surface
tension in aqueous solution of <30 mN/m, an interfacial tension in aqueous
solution with respect to the fluorocarbon of <25 mN/m, and a concentration
of <0.3%.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|